MetaCap

Assembly Biosciences (ASMB) vs BlossomHill Therapeutics (BLSM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BlossomHill Therapeutics is the larger company by market cap ($461.2 million vs $454.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASMB-16.83%BLSM-9.31%
+72%+20%-32%
Aug 7, 20261 yearNov 20, 2026
ASMB-16.83%BLSM-9.31%
+65%+18%-30%
Aug 3, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASMB versus BLSM key metrics
MetricASMBBLSM
Share price$22.19$14.51
Market cap$454.39M$461.20M
1-day change-1.38%+0.69%
YTD return-34.75%—
1-year return-42.36%—
5-year return-21.31%—
P/E ratio (TTM)29.59—
EPS (TTM)$0.75$-10.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.30M—
Revenue growth (YoY)+153.52%—
Net income (latest FY)$-6.12M—
Operating margin-16.76%—
Net margin-8.47%—
52-week high$39.65$27.99
52-week low$19.20$11.02
Distance from 52-week high-44.04%-48.16%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+130.73%+143.97%
Average volume309.38K193.15K
Shares outstanding20.48M31.78M
Employees7369
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Assembly Biosciences

ASMB stock →

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.

Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees

About BlossomHill Therapeutics

BLSM stock →

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

ASMB vs BLSM FAQ

Which is bigger, Assembly Biosciences or BlossomHill Therapeutics?

BlossomHill Therapeutics (BLSM) is larger, with a market capitalization of $461.20M compared with $454.39M for Assembly Biosciences (ASMB).

Are Assembly Biosciences and BlossomHill Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons